Conversión a sirolimus

Nefrologia

Volumn 26, Issue SUPPL.2, 2006, Pages 52-63

  Ruiz, Juan Carlos ^a   Alonso, A ^b   Arias, M ^a   Campistol, J M ^c   Gonzalez Molina M ^d   Gonzalez Posada J M ^e   Grinyo, J M ^f   Morales, J M ^g   Oppenheimer, F ^c   Sanchez Fructuoso A ^h   Sanchez Plumed J ⁱ  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c Hospital Clinic   (Spain)

^d Hospital Carlos Haya   (Spain)

^e Hospital Universitario Tenerife   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h Hospital Clínico   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CORTICOSTEROID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL (TOPIC); DISEASE PREDISPOSITION; DRUG ADMINISTRATION; DRUG ANTAGONISM; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOCOMPROMISED PATIENT; INCIDENCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; REVIEW;

ADRENAL CORTEX HORMONES; CALCINEURIN; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; HYPERTENSION; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; SIROLIMUS;

EID: 55949096387     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andrés A y cols.: Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant May; 2 (5): 436-442, 2002.
2. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P y cols.: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation Apr 15; 67 (7): 1036-1042, 1999.
3. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D y cols.: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation Apr 15; 67 (7): 1252-1260, 2000.
4. Sennesael JJ, Bosmans JL, Bogers JP, Verbeelen D, Verpooten GA: Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation Dec 15; 80 (11): 1578-1585, 2005.
5. Bumbea V, Kamar N, Ribes D, Espósito L, Modesto A, Guitard J y cols.: Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant Nov; 20 (11): 2517-2523, 2005.
6. Diekmann F, Waiser J, Fritsche L, Dragun D, Neumayer HH, Budde K: Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity. Transplant Proc Nov; 33 (7-8): 3234-3235, 2001.
7. Egidi MF, Cowan PA, Naseer A, Gaber AO: Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc May; 35 (3 Supl.): 131S-137S, 2003.
8. Weber T, Abendroth D, Schelzig H: Rapamycin rescue therapy in patients after kidney transplantation: first clinical experience. Transpl Int Feb; 18 (2): 151-156, 2005.
9. Wu MS, Chang CT, Hung CC. Rapamycin in patients with chronic renal allograft dysfunction. Clin Transplant Apr; 19 (2): 236-242, 2005.
10. Wyzgal J, Paczek L, Senatorski G, Zygier J, Rowinski W, Szmidt J y cols.: Sirolimus rescue treatment in calcineurin-inhibitor nephrotoxicity after kidney transplantation. Transplant Proc Dec; 34 (8): 3185-3187, 2002.
11. Schena PJ, Walli RK, Pascoe MD, Alberu J, Rial MC: A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients. American Transplant Congress, Seattle, Washington. 2005. Ref Type: Abstract
12. Diekmann F, Campistol JM: Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2005 Dec 16.
13. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A: Risk factors for late kidney allograft failure. Kidney Int Nov; 62 (5): 1848-1854, 2002.
14. Paul LC. Chronic allograft nephropathy: an update. Kidney Int Sep; 56 (3): 783-793, 1999.
15. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med Dec 11; 349 (24): 2326-2333, 2003.
16. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation Aug 27; 78 (4): 557-565, 2004.
17. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T y cols.: The Banff 97 working classification of renal allograft pathology. Kidney Int Feb; 55 (2): 713-723, 1999.
18. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int Jul; 62 (1): 311-318, 2002.
19. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ y cols.: Effect of histological damage on long-term kidney transplant outcome. Transplantation Feb 27; 71 (4): 515-523, 2001.
20. Serón D, Moreso F, Ramón JM, Hueso M, Condom E, Fulladosa X y cols.: Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation May 15; 69 (9): 1849-1855, 2000.
21. Moreso F, López M, Vallejos A, Giordani C, Riera L, Fulladosa X y cols.: Serial protocol biopsies to quantify the progression of chronic transplant nephropathy in stable renal allografts. Am J Transplant May; 1 (1): 82-88, 2001.
22. Chapman JR, O'Connell PJ, Nankivell BJ: Chronic renal allograft dysfunction. J Am Soc Nephrol Oct; 16 (10): 3015-3026, 2005.
23. Flechner SM, Kurian SM, Solez K, Cook DJ, Burke JT, Rollin H y cols.: De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant Nov; 4 (11): 1776-1785, 2004.
24. Ruiz JC, Campistol JM, Grinyo JM, Mota A, Prats D, Gutiérrez JA y cols.: Early cyclosporine a withdrawal in kidneytransplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation Nov 15; 78 (9): 1312-1318, 2004.
25. Mota A, Arias M, Taskinen EI, Paavonen T, Brault Y, Legendre C y cols.: Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant Jun; 4 (6): 953-961, 2004.
26. Stallone G, Di PS, Schena A, Infante B, Grandaliano G, Battaglia M y cols.: Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation Apr 15; 75 (7): 998-1003, 2003.
27. Domínguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS: Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation Oct 27; 70 (8): 1244-1247, 2000.
28. Morelon E, Kreis H: Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc May; 35 (3 Supl.): 52S-57S, 2003.
29. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM: Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant Nov; 4 (11): 1869-1875, 2004.
30. Renders L, Steinbach R, Valerius T, Schocklmann HO, Kunzendorf U. Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. Kidney Blood Press Res 27 (3): 181-185, 2004.
31. Citterlo F, Scata MC, Violi P, Romagnoli J, Pozzetto U, Nanni G y cols.: Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 35 (4): 1292-1294, 2003.
32. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW y cols.: Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med Sep 4; 349 (10): 931-940, 2003.
33. Magee C, Pascual M: The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med Sep 4; 349 (10): 994-996, 2003.
34. Fernández-Valls M, González-Vílchez F, Vázquez de Prada JA, Ruano J, Ruisanchez C, Martín-Durán R: Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center. Transplant Proc Nov; 37 (9): 4021-4023, 2005.
35. Hunt J, Lerman M, Magee MJ, Dewey TM, Herbert M, Mack MJ: Improvement of renal dysfunction by conversion from calcineurin inhibitors to sirolimus after heart transplantation. J Heart Lung Transplant Nov; 24 (11): 1863-1867, 2005.
36. Sánchez EQ, Martín AP, Ikegami T, Uemura T, Narasimhan G, Goldstein RM y cols.: Sirolimus conversion after liver transplantation: improvement in measured glomerular filtration rate after 2 years. Transplant Proc Dec; 37 (10): 4416-4423, 2005.
37. Zakliczynski M, Nozynski J, Zakliczynska H, Rozentryt P, Zembala M: Deterioration of renal function after replacement of cyclosporine with sirolimus in five patients with severe renal impairment late after heart transplantation. Transplant Proc Sep; 35 (6): 2331-2332, 2003.
38. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP: Risk of neoplasia in renal transplant patients. Lancet Aug 12; 346 (8972): 403-406, 1995.
39. Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf Aug; 23 (2): 101-113, 2000.
40. Penn I: Cancers in renal transplant recipients. Adv Ren Replace Ther Apr; 7 (2): 147-156, 2000.
41. Buell JF, Gross TG, Woodle ES: Malignancy after transplantation. Transplantation Oct 15; 80 (2 Supl.): S254-S264, 2005.
42. Guba M, Von BP, Steinbauer M, Koehl G, Flegel S, Hornung M y cols.: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med Feb; 8 (2): 128-135, 2002.
43. Kahan BD: Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc May; 35 (3 Supl.): 37S-51S, 2003.
44. Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D y cols.: Low incidence of malignancy among sirolimus/ cyclosporine-treated renal transplant recipients. Transplantation Sep 27; 80 (6): 749-758, 2005.
45. Mathew T, Kreis H, Friend P: Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant Aug; 18 (4): 446-449, 2004.
46. Campistol JM, Eris J, Oberbauer R, Friend P, Hutchison B, Morales JM y cols.: Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol Feb; 17 (2): 581-589, 2006.
47. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation Oct 15; 80 (7): 883-889, 2005.
48. Campistol JM, Gutiérrez-Dalmau A, Torregrosa JV: Conversion to sirolimus: a successful treatment for post-transplantation Kaposi's sarcoma. Transplantation Mar 15; 77 (5): 760-762, 2004.
49. Stallone G, Schena A, Infante B, Di PS, Loverre A, Maggio G y cols.: Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med Mar 31; 352 (13): 1317-1323, 2005.
50. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger M: Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc Mar; 37 (2): 964-966, 2005.
51. Gutiérrez-Dalmau A, Sánchez-Fructuoso A, Sanz-Guajardo A, Mazuecos A, Franco A, Rial MC y cols.: Efficacy of Conversion to Sirolimus in Post-transplantation Kaposi's Sarcoma. Transplant Proc Nov; 37 (9): 3836-3838, 2005.
52. Zaltzman JS, Prasad R, Chun K, Jothy S: Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus. Nephrol Dial Transplant Aug; 20 (8): 1748-1751, 2005.
53. García VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, García CD y cols.: Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int Mar; 16 (3): 202-206, 2003.
54. Al-Akash SI, Al Makadma AS, Al Omari MG: Rapid response to rituximab in a pediatric liver transplant recipient with post-transplant lymphoproliferative disease and maintenance with sirolimus monotherapy. Pediatr Transplant Apr; 9 (2): 249-253, 2005.
55. Euvrard S, Ulrich C, Lefrancois N: Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg Apr; 30 (4 Pt 2): 628-633, 2004.
56. th ed. Los Angeles: Lippincott Williams and Wilkins. pp. 169-192, 2005.
57. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation Sep 15; 72 (5): 777-786, 2001.
58. Morales JM, Andrés A, Rengel M, Rodicio JL: Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 16 Supl. 1: 121-4, 2001.
59. Mulay AV, Hussain N, Fergusson D, Knoll GA: Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant Jul; 5 (7): 1748-1756, 2005.
60. Teutonico A, Schena PF, Di PS: Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol Oct; 16 (10): 3128-3135, 2005.
61. Havrdova T, Saudek F, Boucek P, Adamec M, Koznarova R, Jedinakova T y cols.: Metabolic effect of sirolimus versus mycophenolate mofetil on pancreatic graft function in the early post-transplant period. Transplant Proc Oct; 37 (8): 3544-3545, 2005.
62. Abraham KA, Little MA, Dorman AM, Walshe JJ: Hemolyticuremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 13 (6): 443-447, 2000.
63. Kohli HS, Sud K, Jha V, Gupta KL, Minz M, Joshi K y cols.: Cyclosporin-induced haemolytic-uraemic syndrome presenting as primary graft dysfunction. Nephrol Dial Transplant Nov; 13 (11): 2940-2942, 1998.
64. Franco A, Hernández D, Capdevilla L, Errasti P, González M, Ruiz JC y cols.: De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus. Transplant Proc Aug; 35 (5): 1764-1766, 2003.
65. Gutiérrez de la FC, Sola E, Alférez MJ, Navarro A, Cabello M, Burgos D y cols.: [De novo hemolytic uremic syndrome in a kidney-pancreas recipient in the postoperative period]. Nefrología 24 Supl. 3: 3-6, 2004.
66. Yango A, Morrissey P, Monaco A, Butera J, Gohh RY: Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. Clin Nephrol Jul; 58 (1): 77-78, 2002.
67. Heering P, Deppe CE, Farokhzad F, Helmchen U, Grabensee B: Hemolytic uremic syndrome after renal transplantation: immunosuppressive therapy with rapamycin. Nephron May; 91 (1): 177, 2002.
68. Abraham KA, Little MA, Dorman AM, Walshe JJ: Hemolyticuremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 13 (6): 443-447, 2000.
69. Grupp C, Schmidt F, Braun F, Lorf T, Ringe B, Muller GA: Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation -is tacrolimus the answer? Nephrol Dial Transplant Jul; 13 (7): 1629-1631, 1998.
70. McGregor DO, Robson RA, Lynn KL: Haemolytic-uraemic syndrome in a renal transplant recipient treated by conversion to mycophenolate mofetil. Nephron Nov; 80 (3): 365-366, 1998.
71. Agarwal DK, Gulati S, Mehta A, Kumar A, Sharma RK, Mehta B y cols.: Mycophenolate mofetil as an effective alternative to cyclosporin in post-transplant haemolytic uraemic syndrome. Nephrol Dial Transplant Dec; 15 (12): 2064-2065, 2000.
72. Said T, al-Mousawi M, Samhan M, Lao M: Cyclosporin conversion to CellCept in a cadaveric renal allograft recipient with hemolytic uremic syndrome. Transplant Proc Dec; 31 (8): 3295-3297, 1999.
73. Franz M, Regele H, Schmaldienst S, Stummvoll HK, Horl WH, Pohanka E: Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy? Transplantation Nov 15; 66 (9): 1258-1262, 1998.
74. Oyen O, Strom EH, Midtvedt K, Bentdal O, Hartmann A, Bergan S y cols.: Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. Am J Transplant Feb; 6 (2): 412-418, 2006.
75. Barone GW, Gurley BJ, Bul-Ezz SR, Gokden N: Sirolimus-induced thrombotic microangiopathy in a renal transplant recipient. Am J Kidney Dis Jul; 42 (1): 202-206, 2003.
76. Pelle G, Xu Y, Khoury N, Mougenot B, Rondeau E: Thrombotic microangiopathy in marginal kidneys after sirolimus use. Am J Kidney Dis Dec; 46 (6): 1124-1128, 2005.
77. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E y cols.: Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant Oct; 5 (10): 2441-2447, 2005.
78. Fortin MC, Raymond MA, Madore F, Fugere JA, Paquet M, St-Louis G y cols.: Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am J Transplant Jun; 4 (6): 946-952, 2004.
79. Robson M, Cote I, Abbs I, Koffman G, Goldsmith D: Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? Am J Transplant Mar; 3 (3): 324-327, 2003.
80. Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E y cols.: Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant Jul; 11 (7): 551-557, 2005.
81. Paramesh AS, Grosskreutz C, Florman SS, Gondolesi GE, Sharma S, Kaufman SS y cols.: Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. Transplantation Jan 15; 77 (1): 129-131, 2004.
82. Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ: Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Clin Transplant 18 Supl. 12: 61-66.: 61-6, 2004.
83. Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H y cols.: Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit Dec; 23 (6): 717-721, 2001.
84. Diekmann F, Gutiérrez-Dalmau A, Torregrosa JV, Oppenheimer F, Campistol JM: Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation- a pilot experience. Transplantation Nov 15; 80 (9): 1344-1348, 2005.
85. Ruiz JC, Diekmann F, Campistol JM, Sánchez-Fructuoso A, Rivera C, Oliver J y cols.: Evolution of Proteinuria After Conversion From Calcineurin Inhibitors (CNI) to Sirolimus (SRL) in Renal Transplant Patients: a Multicenter Study. Transplant Proc Nov; 37 (9): 3833-3835, 2005.
86. Izzedine H, Brocheriou I, Frances C: Post-transplantation proteinuria and sirolimus. N Engl J Med Nov 10; 353 (19): 2088-2089, 2005.
87. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C: Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation Nov 15; 80 (9): 1198-1203, 2005.